Breaking News Instant updates and real-time market news.

XPO

XPO Logistics

$82.92

1.34 (1.64%)

, SAVE

Spirit Airlines

$39.64

-0.47 (-1.17%)

18:54
01/15/20
01/15
18:54
01/15/20
18:54

Fly Intel: After Hours Movers

HIGHER: XPO Logistics (XPO) up 15.7% after announcing it is exploring strategic alternatives... Spirit Airlines (SAVE) up 2.8% after raising Q4 TRASM outlook. DOWN AFTER EARNINGS: Alcoa (AA) down 3.2%. ALSO LOWER: Acordia Therapeutics (ACOR) down 5.2% after selling stock for holders... Global Water Resources (GWRS) down 4.2% after equity offering... Alamos Gold (AGI) down 1.2% after being downgraded at Credit Suisse. Movers as of 18:30ET.

XPO

XPO Logistics

$82.92

1.34 (1.64%)

SAVE

Spirit Airlines

$39.64

-0.47 (-1.17%)

AA

Alcoa

$20.17

-0.19 (-0.93%)

ACOR

Acorda Therapeutics

$2.12

-0.215 (-9.21%)

GWRS

Global Water Resources

$12.79

0.04 (0.31%)

AGI

Alamos Gold

$5.76

0.17 (3.04%)

  • 15

    Jan

  • 15

    Jan

  • 22

    Jan

  • 11

    Feb

  • 16

    Jan

XPO XPO Logistics
$82.92

1.34 (1.64%)

10/30/19
RHCO
10/30/19
NO CHANGE
Target $95
RHCO
Buy
XPO Logistics price target raised to $95 from $80 at SunTrust
SunTrust analyst Stephanie Benjamin raised her price target on XPO Logistics to $95 and kept her Buy rating after its Q3 earnings beat. The analyst notes that in spite of the softer macro environment, she expects the company to outperform its peer group thanks to its "technology-driven cost improvement initiatives, favorable comps, and new customer wins."
01/10/20
OPCO
01/10/20
NO CHANGE
Target $90
OPCO
Outperform
Oppenheimer constructive on XPO Logistics in 2020 ahead of guidance
Oppenheimer analyst Scott Schneeberger reiterated his Outperform rating and $90 price target on XPO Logistics, stating that he anticipates the company will initiate 2020 adjusted EBITDA guidance that will encompass his estimate of $1.775B-$1.79B. While this view represents year-over-year growth acceleration, he also believes it may ultimately prove conservative should XPO effectively leverage new business wins, Schneeberger added.
10/30/19
FBCO
10/30/19
NO CHANGE
Target $90
FBCO
Outperform
XPO Logistics price target raised to $90 from $79 at Credit Suisse
Credit Suisse analyst Allison Landry raised her price target for XPO Logistics to $90 from $79 and maintained an Outperform rating, saying the company's tech initiatives helped support a Q3 beat, with better than forecast margins offsetting a weaker top line. While the company is not immune to cyclical pressures, its 10 revenue and cost initiatives that have the potential to generate $700M-$1B of incremental profit by 2022 are largely independent ofthe macro, with 6 of the levers being rooted in technology investments, Landry tells investors in a research note.
11/12/19
SBSH
11/12/19
NO CHANGE
SBSH
Buy
Citi sees 'compelling case' for XPO Logistics in 2020
After visiting management, Citi analyst Christian Wetherbee believes there is a "compelling case developing" for XPO Logistics in 2020, "assuming a relatively stable macro backdrop." In 2020, XPO laps two major customer losses, will implement multiple cost savings initiatives, and starts with a "meaningful valuation discount" versus peers, Wetherbee tells investors in a research note. As such, the analyst thinks XPO's EBITDA growth can accelerate in 2020. He believes the company's current valuation discount can narrow, "leading to solid upside," and reiterates a Buy rating on the shares with a new price target of $100.
SAVE Spirit Airlines
$39.64

-0.47 (-1.17%)

12/02/19
12/02/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Splunk (SPLK) upgraded to Buy from Neutral at Goldman Sachs with analyst Christopher Merwin saying after a "strong" fiscal Q3 report, the he "several catalysts" for Splunk (SPLK) shares to positively re-rate over the next 12 months. 2. Altria Group (MO) upgraded to Buy from Neutral at Citi with analyst Adam Spielman saying it is becoming hard to argue that "tobacco is being disrupted." 3. Plains All American (PAA) upgraded to Outperform from Neutral at Baird. 4. TreeHouse (THS) upgraded to Outperform from Market Perform at William Blair with analyst Jon Andersen saying private brands puts TreeHouse into a "large industry with ample runway for growth." 5. Spirit Airlines (SAVE) upgraded to Buy from Neutral at Buckingham with analyst Daniel McKenzie saying he downgraded the stock in September, arguing that Spirit's revenue outlook was set to worsen on the return of the 737 MAX (BA), the rollout of JetBlue's (JBLU) Fare Families 2.0 and competitive capacity that doubled, but says revenue worries are dissipating on reduced competitive capacity and revenue initiatives are set to finally gain traction in 2020. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/09/20
VERT
01/09/20
UPGRADE
VERT
Buy
Spirit Airlines upgraded to Buy from Hold at Vertical Research
Vertical Research upgraded Spirit Airlines to Buy from Hold.
12/16/19
COWN
12/16/19
NO CHANGE
Target $50
COWN
Outperform
Spirit Airlines price target raised to $50 from $48 at Cowen
Cowen analyst Helane Becker raised her price target on Spirit Airlines to $50 from $48 and called it a Best Idea for 2020. The analyst believes its strategy of stimulating demand through low fares is profitable and repeatable, due to growing unit cost advantage versus peers, improving operations should benefit consumer sentiment and unit costs. Becker reiterated her Outperform rating on Spirit Airlines shares.
01/06/20
SPHN
01/06/20
NO CHANGE
SPHN
United Airlines named a Best Idea as Stephens transfers airline coverage
Stephens transitioned coverage of the airline group to Scott Schoenhaus, who lowered his 2020 estimates for JetBlue (JBLU), Southwest (LUV) and Spirit Airlines (SAVE) and raised his estimates for United Airlines (UAL), which he also named as a Best Idea. He believes harsh weather conditions and some pricing actions around the peak travel weeks created near-term headwinds for some carriers and he continues to believe in an overall lackluster setup for the airline group in the first half of the year. Schoenhaus also took over coverage of American (AAL), Delta (DAL) and SkyWest (SKYW).
AA Alcoa
$20.17

-0.19 (-0.93%)

12/17/19
BMOC
12/17/19
DOWNGRADE
Target $23
BMOC
Market Perform
Alcoa downgraded to Market Perform from Outperform at BMO Capital
BMO Capital analyst David Gagliano downgraded Alcoa to Market Perform from Outperform with a price target of $23, down from $25. The analyst says BMO's reduced aluminum price forecasts for the entirety of the aluminum supply chain leave "little incremental upside potential" moving forward in the underlying price forecasts. With Alcoa shares highly sensitive to underlying price forecasts, there are limited price-related catalysts to push the stock higher in 2020, Gagliano tells investors in a research note.
12/17/19
12/17/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Pentair (PNR) downgraded to Hold from Buy at Stifel with analyst Nathan Jones saying Pentair's 2020 prospects look improved over 2019 where discrete headwinds, particularly in the Aquatics business, create easy comparisons in the first half of 2020. 2. Alcoa (AA) downgraded to Market Perform from Outperform at BMO Capital with analyst David Gagliano saying BMO's reduced aluminum price forecasts for the entirety of the aluminum supply chain leave "little incremental upside potential" moving forward in the underlying price forecasts. 3. SciPlay (SCPL) was double downgraded to Sell from Buy at Goldman Sachs while Groupon (GRPN) was downgraded to Sell from Neutral. 4. Lennar (LEN) and Fortune Brands (FBHS) were downgraded to Sector Perform from Outperform at RBC Capital while D.R. Horton (DHI) was downgraded to Underperform from Sector Perform. 5. Alexion (ALXN) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Matthew Harrison saying while he thinks the company can effectively transition Soliris to Ultomiris and maintain its large and emerging neurology franchise, he does not see the "major overhang of concentration risk" as one the company will be able to address in the near-term. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/20/19
RILY
12/20/19
NO CHANGE
Target $25
RILY
Buy
Alcoa price target lowered to $25 from $28 at B. Riley FBR
B. Riley FBR analyst Lucas Pipes lowered his price target for Buy-rated Alcoa (AA) to $25 from $28 and for Buy-rated Century Aluminum (CENX) to $11 from $12. The new price targets reflect tweaks to FBR's commodity price assumptions for aluminum and alumina. However, the analyst notes his firm's long-term price deck for aluminum is still 11% above spot prices, reflecting optimism that lower exchange inventories in China and an improved economic outlook could contribute to a price recovery.
11/13/19
11/13/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Skyworks (SWKS) downgraded to Hold from Buy at Canaccord with analyst T. Michael Walkley saying he believes the company is well positioned to grow faster than the broader semi market for the next several years due to smartphone mix among Chinese OEMs requiring integrated Rf solutions, growing IoT opportunities, and the ramping 5G market opportunities. 2. D.R. Horton (DHI) downgraded to Neutral from Buy at Buckingham. 3. Diplomat Pharmacy (DPLO) downgraded to Equal Weight from Overweight at Barclays with analyst Steven Valiquette saying Diplomat's strategic review is ongoing, which could lead to a sale of the entire company, or simultaneous asset sales that could unlock value. 4. Alcoa (AA) downgraded to Underperform from Neutral at BofA/Merrill with analyst Timna Tanners citing limited catalysts and a cautious aluminum view, adding that while the stock price has risen about 16% since reporting Q3, aluminum price was up only about 6% in that time frame. 5. J.M. Smucker (SJM) downgraded to Underperform from Neutral at Credit Suisse with analyst Robert Moskow saying with consensus already below management's FY20 guidance of $8.35-$8.55, it is fair to say that J.M. Smucker is already an out-of-favor stock, but he believes that consensus and the market underestimate the extent to which earnings will need to be revised lower as structural challenges continue to mount. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ACOR Acorda Therapeutics
$2.12

-0.215 (-9.21%)

10/24/19
JPMS
10/24/19
DOWNGRADE
JPMS
Underweight
JPMorgan downgrades Acorda to Underweight on disappointing Inbrija launch
JPMorgan analyst Cory Kasimov downgraded Acorda Therapeutics to Underweight from Neutral without a price target. Inbrija's commercial launch continues to disappoint, Kasimov tells investors in a research note. "We simply don't see a near term fix for this product or company," admits the analyst. A solution would be a takeout of Acorda, but potential buyers would likely want to see sales tick up in a meaningful way before making a move, he adds. Kasimov believes that with a $300M convert "looming and sales struggling," Acorda's "path forward could become increasingly difficult."
10/24/19
JPMS
10/24/19
DOWNGRADE
JPMS
Underweight
Acorda Therapeutics downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Cory Kasimov downgraded Acorda Therapeutics to Underweight from Neutral.
09/30/19
BOFA
09/30/19
DOWNGRADE
Target $5
BOFA
Underperform
Adamas Pharmaceuticals downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill analyst Tazeen Ahmad downgraded Adamas Pharmaceuticals (ADMS) to Underperform and lowered his price target to $5 from $9. The analyst cites indications of a "limited" uptake of ADS-5102 by doctors in multiple sclerosis, adding that the drug's phase 2 trial data have demonstrated comparable response and more safety concerns than the current standard-of-care with Ampyra made by Acorda Therapeutics (ACOR). Ahmad is also increasing his discontinuation rate assumption for '5102 to 30% and lowers his risk-adjusted peak sales estimate to $324M from $365M.
08/14/19
HCWC
08/14/19
DOWNGRADE
Target $6
HCWC
Neutral
Acorda Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju downgraded Acorda Therapeutics to Neutral from Buy and lowered his price target for the shares to $6 from $31. The "anemic" sales trajectory for Inbrija is concerning, particularly in light of the $323.8M in convertible notes maturing June 15, 2021, Selvaraju tells investors in a research note. Inbrija sales are not growing fast enough to pick up the slack Amprya is leaving behind, says the analyst. Further, he believes Acorda is "running out of runway" because of the impending maturity of the 2021 convertible notes. As such, Selvaraju feels the stock's risk profile is not currently appealing.
GWRS Global Water Resources
$12.79

0.04 (0.31%)

AGI Alamos Gold
$5.76

0.17 (3.04%)

01/15/20
FBCO
01/15/20
DOWNGRADE
Target $7.5
FBCO
Neutral
Alamos Gold downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse downgraded Alamos Gold to Neutral from Outperform with a $7.50 price target.
01/15/20
FBCO
01/15/20
DOWNGRADE
Target $7.5
FBCO
Neutral
Alamos Gold downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse analyst Fahad Tariq downgraded Alamos Gold to Neutral from Outperform with a price target of $7.50, down from $10. The analyst cited elevated execution risk, including uncertainty around the Kirazli constructionrestart and the multi-month Young-Davidson tie-in in Q2, and limited free cash flow in 2020. Tariq also noted, however, that Alamos Gold operates in lower-risk jurisdictions and has a strong balance sheet with no debt.
01/15/20
FBCO
01/15/20
NO CHANGE
FBCO
Agnico, Newmont, Endeavour named top 2020 gold picks at Credit Suisse
Credit Suisse analyst Fahad Tariq expects gold prices to perform well in 2020. Despite some near-term optimism on equities and economic conditions, the analyst sees a "risk-off skew" in 2020 amid continued uncertainty on the U.S.-China trade war, Brexit, and fears of a global economic slowdown or recession. Tariq expects 2020 gold prices to average ~$1,540 per ounce, peaking in the first half of the year at $1,560 and then gradually falling to $1,525 by year-end. The analyst's top picks in Precious Metals for 2020 are Agnico Eagle (AEM), Newmont Goldcorp (NEM) and Endeavour Mining (EDVMF). Along with the sector outlook, Tariq upgraded Barrick Gold (GOLD) to Outperform from Neutral, downgraded Alamos Gold (AGI) and Centerra Gold (CAGDF) to Neutral from Outperform, and downgraded Eldorado Gold (EGO) to Underperform from Neutral.
12/04/19
RBCM
12/04/19
INITIATION
Target $6.5
RBCM
Sector Perform
Alamos Gold assumed with a Sector Perform at RBC Capital
RBC Capital analyst Josh Wolfson assumed coverage of Alamos Gold with a Sector Perform rating and $6.50 price target. Upcoming changes within the company's operating portfolio outline increased capital and operating cost uncertainties in 2020, says the analyst, who views its upcoming guidance as a risk.

TODAY'S FREE FLY STORIES

TLGT

Teligent

$0.40

-0.0025 (-0.62%)

15:53
01/18/20
01/18
15:53
01/18/20
15:53
Conference/Events
Teligent to hold a special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

AYTU

Aytu BioScience

$0.80

0.0014 (0.18%)

15:48
01/18/20
01/18
15:48
01/18/20
15:48
Conference/Events
Aytu BioScience to hold a special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

DVA

DaVita

$79.45

0.43 (0.54%)

15:32
01/18/20
01/18
15:32
01/18/20
15:32
Conference/Events
DaVita to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

TSM

TSMC

$58.58

-0.18 (-0.31%)

09:16
01/18/20
01/18
09:16
01/18/20
09:16
Periodicals
Taiwan tech stocks can ignore China's bluster for now, Barron's says »

China's government…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KKR

KKR

$31.20

0.7 (2.30%)

, APO

Apollo Global

$50.35

1.26 (2.57%)

09:03
01/18/20
01/18
09:03
01/18/20
09:03
Periodicals
KKR undervalued compared with peers, Barron's says »

KKR (KKR) gained 50% last…

KKR

KKR

$31.20

0.7 (2.30%)

APO

Apollo Global

$50.35

1.26 (2.57%)

ARES

Ares Management

$37.29

0.47 (1.28%)

BX

Blackstone

$60.79

0.62 (1.03%)

CG

Carlyle Group

$33.30

0.36 (1.09%)

HLNE

Hamilton Lane

$67.25

-0.02 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 30

    Jan

  • 31

    Jan

  • 31

    Jan

  • 04

    Feb

  • 04

    Feb

  • 05

    Feb

  • 13

    Feb

  • 17

    Feb

  • 26

    Feb

SPCE

Virgin Galactic

$15.65

0.685 (4.58%)

, TWNK

Hostess Brands

$14.03

0.02 (0.14%)

08:56
01/18/20
01/18
08:56
01/18/20
08:56
Periodicals
'Blank-check' companies hot on Wall Street, Barron's says »

More than a quarter of…

SPCE

Virgin Galactic

$15.65

0.685 (4.58%)

TWNK

Hostess Brands

$14.03

0.02 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 04

    Mar

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

, NFLX

Netflix

$339.56

0.89 (0.26%)

08:47
01/18/20
01/18
08:47
01/18/20
08:47
Periodicals
Peacock's pricing might be 'killer feature,' Barron's says »

This week, Peacock…

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

NFLX

Netflix

$339.56

0.89 (0.26%)

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$47.48

0.62 (1.32%)

GOOGL

Alphabet Class A

$1,479.12

29.29 (2.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 22

    Jan

  • 23

    Jan

  • 03

    Feb

  • 03

    Feb

  • 10

    Feb

JWN

Nordstrom

$40.34

-0.15 (-0.37%)

, WMT

Walmart

$114.93

-0.96 (-0.83%)

08:36
01/18/20
01/18
08:36
01/18/20
08:36
Periodicals
Casper IPO highlights tech's promise, troubles, Barron' says »

Mattresses have been…

JWN

Nordstrom

$40.34

-0.15 (-0.37%)

WMT

Walmart

$114.93

-0.96 (-0.83%)

CSPR

Casper Sleep

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 18

    Feb

BA

Boeing

$324.11

-7.89 (-2.38%)

, DDAIF

Daimler AG

$0.00

(0.00%)

08:12
01/18/20
01/18
08:12
01/18/20
08:12
On The Fly
Week in Review: How Trump's policies moved stocks »

Catch up on the top…

BA

Boeing

$324.11

-7.89 (-2.38%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$13.76

-0.14 (-1.01%)

VWAGY

Volkswagen

$0.00

(0.00%)

FSLR

First Solar

$53.51

-0.42 (-0.78%)

AAPL

Apple

$318.66

3.33 (1.06%)

DQ

Daqo New Energy

$53.61

-0.025 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 29

    Jan

SPOT

Spotify

$148.20

-3.59 (-2.37%)

18:15
01/17/20
01/17
18:15
01/17/20
18:15
Periodicals
Spotify in talks to acquire The Ringer, WSJ reports »

Spotify is in discussions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

CE

Celanese

$117.54

-0.53 (-0.45%)

18:00
01/17/20
01/17
18:00
01/17/20
18:00
Hot Stocks
Celanese announces acetyl intermediates price increases »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

BYND

Beyond Meat

$109.20

-1.16 (-1.05%)

17:58
01/17/20
01/17
17:58
01/17/20
17:58
Periodicals
Beyond Meat rival gets green light in Canada, The Star says »

Impossible Foods, a maker…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBD

Diebold

$11.09

-0.49 (-4.23%)

17:42
01/17/20
01/17
17:42
01/17/20
17:42
Periodicals
Breaking Periodicals news story on Diebold »

Diebold Nixdorf divests…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEF

iShares 7-10 Year Treasury Bond ETF

$111.28

-0.13 (-0.12%)

, SHY

iShares 1-3 Year Treasury Bond

$84.73

-0.005 (-0.01%)

17:32
01/17/20
01/17
17:32
01/17/20
17:32
General news
Weekly CFTC Commitment of Traders highlights »

2-YEAR U.S. TREASURY net…

IEF

iShares 7-10 Year Treasury Bond ETF

$111.28

-0.13 (-0.12%)

SHY

iShares 1-3 Year Treasury Bond

$84.73

-0.005 (-0.01%)

SPY

SPDR S&P 500 ETF Trust

$331.98

1.08 (0.33%)

SLV

iShares Silver Trust

$16.82

0.04 (0.24%)

GLD

SPDR Gold Shares

$146.59

0.29 (0.20%)

FXE

Euro Currency Trust

$105.10

-0.43 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBSFY

Ubisoft

$0.00

(0.00%)

17:32
01/17/20
01/17
17:32
01/17/20
17:32
Periodicals
Ubisoft to restructure editorial team after difficult 2019, VGC reports »

Ubisoft intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Feb

IMVT

Immunovant

$17.04

-0.01 (-0.06%)

17:27
01/17/20
01/17
17:27
01/17/20
17:27
Syndicate
Breaking Syndicate news story on Immunovant »

Immunovant files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TBLT

ToughBuilt

$0.33

-0.0255 (-7.11%)

17:20
01/17/20
01/17
17:20
01/17/20
17:20
Syndicate
ToughBuilt files to sell common stock, no amount given »

Maxim acted as sole book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYO

Myomo

$0.32

0.0062 (1.98%)

17:18
01/17/20
01/17
17:18
01/17/20
17:18
Conference/Events
Myomo to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

SRRA

Sierra Oncology

$0.40

-0.02 (-4.76%)

17:14
01/17/20
01/17
17:14
01/17/20
17:14
Conference/Events
Sierra Oncology to host virtual special shareholder meeting »

Virtual Special…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

SRNE

Sorrento Therapeutics

$4.26

-0.15 (-3.40%)

17:10
01/17/20
01/17
17:10
01/17/20
17:10
Syndicate
Breaking Syndicate news story on Sorrento Therapeutics »

Sorrento Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKER

Akers Biosciences

$3.45

-0.1 (-2.82%)

17:01
01/17/20
01/17
17:01
01/17/20
17:01
Hot Stocks
Akers Biosciences reaches settlement agreements on two derivative actions »

Akers Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECA

Encana

$4.09

-0.18 (-4.22%)

16:40
01/17/20
01/17
16:40
01/17/20
16:40
Hot Stocks
Encana receives court approval for reorganization »

Encana Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

MBRX

Moleculin Biotech

$0.96

0.0122 (1.29%)

16:38
01/17/20
01/17
16:38
01/17/20
16:38
Syndicate
Breaking Syndicate news story on Moleculin Biotech »

Moleculin Biotech files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VOD

Vodafone

$20.07

-0.225 (-1.11%)

, BT

BT Group

$0.00

(0.00%)

16:37
01/17/20
01/17
16:37
01/17/20
16:37
Periodicals
BT, Vodafone consider urging PM Johnson not to ban Huawei in U.K., Reuters says »

BT Group (BT) and…

VOD

Vodafone

$20.07

-0.225 (-1.11%)

BT

BT Group

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
01/17/20
01/17
16:30
01/17/20
16:30
Options
Preliminary option volume of 28.7M today »

Preliminary option volume…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.